Alcresta Therapeutics, Inc.

Altus Biologics Inc.

Altus Pharmaceuticals Inc.

Merrell Dow Pharmaceuticals

Other

Althea Technologies, Inc.

Allena Pharmaceuticals, Inc.

Ajinomoto Althea, Inc.

Altus Biologies, Inc.

Cystic Fibrosis Foundations Therapeutics, Inc.

Eli Lilly and Company

Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Hoechst Marion Roussel Deutschland Gmbh

Alexey L Margolin

Bhami Shenoy

Robert Gallotto

Chandrika Govardhan

Nancy L St Clair

Kalevi Visuri

Sinikka Uotila

Scott L Rakestraw

Nazar K Khalaf

Mark X Yang

Ian A Tomlinson

Edward D Daugs

Jonathan C Evans

Chi-Hsin Richard King

Paul F Skultety

Margaret Ellen McGrath

Danica Grujic

Hans-Wolfram Flemming

Thomas T Ortyl

Rose A Persichetti

Johannes Nicolaas Koek

Sandra K Stolz-Dunn

Stefan Pierzynowski

Nazer K Khalaf

Frederick T Murray

Anthony Christopher Lee Stevens

Deborah L Delinck

Bhami C Shenoy

Margaret McGrath

Alonzo L Tigner

Thomas He Hilpert

Frederick M Laskovics

Marvin J Sack

John R Lefler

Robert A Hawthorne

Alan G Bina

Sharon K Minish

Deborah Delinck

Chandrika P Govardhan

Margaret Ellen Mcgrath

Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Methods, compositions, and devices for supplying dietary fatty acid needs

Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Compositions of peritoneal dialysis solutions and metabolizing enzymes, and their uses to treat disorders associated with elevated levels of metabolites are disclosed. Animal models of hyperoxalemia are also disclosed.

Compositions, methods, and devices for dialysis

This invention relates to crystals of whole antibodies and fragments thereof, and formulations and compositions comprising such crystals. More particularly, methods are provided for the crystallization of high concentrations of whole antibodies, and fragments thereof, in large batches, and for the preparation of stabilized whole antibody crystals for use alone, or in dry or slurry formulations or compositions. This invention also relates to methods for stabilization, storage and delivery of biologically active whole antibody crystals. The present invention further relates to methods using whole antibody crystals, antibody fragment crystals, or compositions or formulations comprising such crystals for biomedical applications, including biological delivery to humans and animals. More particularly, whole antibody crystals or antibody fragment crystals, or crystal compositions or formulations thereof, are used as a carrier-free delivery system which can slowly release active whole antibodies or fragments thereof, to a subject, where and when they are needed.

Methods of crystallizing antibodies

This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for-the protein crystal formulations and compositions of this invention involve protein delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions.

Stabilized protein crystals, formulations comprising them and methods of making them

Growing community of inventors

Newton, MA, United States of America

Alexey L Margolin